Company BioTime, Inc. Nyse

Equities

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

Sector Other Biotechnology & Medical Research

Inactive Instrument

End-of-day quote Nyse Other stock markets
- ^USD	-

21/05	Lineage Cell Therapeutics, Inc. Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium	CI
09/05	Transcript : Lineage Cell Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs. The Companyâs programs are based on its cell-based technology platform and associated development and manufacturing capabilities. From this platform, the Company designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions. Its neuroscience focused pipeline includes OpRegen, a retinal pigment epithelial cell therapy in phase II a development, for the treatment of geographic atrophy secondary to age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy in phase I/II a development for the treatment of spinal cord injuries; ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and RND1.

USD in Million	2022	Weight	2023	Weight	Delta
Therapeutic Products 100.0 %	15	100.0 %	9	100.0 %	-39.16%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	15	100.0 %	9	100.0 %	-39.16%

Managers	Title	Age	Since
Brian Culley CEO	Chief Executive Officer	53	17/18/17
Jill Howe DFI	Director of Finance/CFO	48	14/22/14
Jennifer Bahr-Davidson COO	Chief Operating Officer	-	01/10/01
Gary Hogge CTO	Chief Tech/Sci/R&D Officer	56	01/18/01
Ioana C. Hone IRC	Investor Relations Contact	-	-
George Samuel LAW	General Counsel	43	01/21/01
Derek Kelaita PRN	Corporate Officer/Principal	-	01/19/01

Members of the board	Title	Age	Since
Neal Bradsher BRD	Director/Board Member	58	01/09/01
Brian Culley CEO	Chief Executive Officer	53	17/18/17
Deborah Andrews BRD	Director/Board Member	66	11/14/11
Don Bailey BRD	Director/Board Member	78	01/20/01
Angus Russell BRD	Director/Board Member	68	09/14/09
Michael Mulroy CHM	Chairman	58	04/14/04
Anula Kusum Jayasuriya BRD	Director/Board Member	67	04/21/04
Dipti Amin BRD	Director/Board Member	60	20/21/20

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	188,823,975	188,001,177 ( 99.56 %)	0	99.56 %

Name	Equities	%	Valuation
Broadwood Capital, Inc. 22.07 %	41,666,255	22.07 %	42 M $
Vanguard Fiduciary Trust Co. 4.435 %	8,373,771	4.435 %	8 M $
BlackRock Advisors LLC 4.330 %	8,175,661	4.330 %	8 M $
Logos Global Management LP 3.310 %	6,250,000	3.310 %	6 M $
Defender Capital LLC 2.631 %	4,967,675	2.631 %	5 M $
Geode Capital Management LLC 1.723 %	3,253,056	1.723 %	3 M $
Raffles Associates LP 1.700 %	3,209,981	1.700 %	3 M $
STATE STREET CORPORATION 1.153 %	2,177,209	1.153 %	2 M $
Prescott General Partners LLC 0.9807 %	1,851,851	0.9807 %	2 M $
MAI Capital Management LLC 0.7896 %	1,490,862	0.7896 %	1 M $

Lineage Cell Therapeutics, Inc.

2173 Salk Avenue Suite 200

92008-7354, Carlsbad

+442 287 8990

http://www.lineagecell.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+38.36%	5.27TCr
LONZA GROUP AG	+39.21%	3.9TCr
IQVIA HOLDINGS INC.	-8.63%	3.85TCr
ALNYLAM PHARMACEUTICALS, INC.	+25.46%	3.04TCr
CELLTRION, INC.	-11.17%	2.64TCr
ICON PUBLIC LIMITED COMPANY	+11.44%	2.61TCr
UNITED THERAPEUTICS CORPORATION	+45.09%	1.42TCr
MEDPACE HOLDINGS, INC.	+32.93%	1.26TCr
BIO-TECHNE CORPORATION	-5.30%	1.15TCr

Other Biotechnology & Medical Research